Suppr超能文献

YM90K:作为一种选择性强效α-氨基-3-羟基-5-甲基异恶唑-4-丙酸/海人藻酸受体拮抗剂的药理学特性

YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.

作者信息

Shimizu-Sasamata M, Kawasaki-Yatsugi S, Okada M, Sakamoto S, Yatsugi S, Togami J, Hatanaka K, Ohmori J, Koshiya K, Usuda S, Murase K

机构信息

Neuroscience Laboratory, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.

出版信息

J Pharmacol Exp Ther. 1996 Jan;276(1):84-92.

PMID:8558460
Abstract

We investigated the pharmacological properties and neuroprotective actions of a novel alpha-amino-3-hydroxy-5-methylisoxazole-y-propionate (AMPA)/kainate receptor antagonist, [6-(1H-imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione hydrochloride (YM90K); formerly YM900], in comparison with those of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). YM90K selectively displaced [3H]-AMPA binding (Ki = 0.084 microM) and was less potent in inhibiting [3H]-kainate (Ki = 2.2 microM), [3H]-L-glutamate (N-methyl-D-aspartate-sensitive site; Ki > 100 microM) and [3H]-glycine (strychnine-insensitive site; Ki = 37 microM) binding to rat brain membranes. YM90K co-injected with AMPA or kainate into the rat striatum protected cholinergic neurons against AMPA- or kainate-induced neurotoxicity. YM90K showed potent suppressive activity against audiogenic seizure in DBA/2 mice; ED50 values of YM90K and NBQX against tonic seizure were 2.54 and 7.17 mg/kg (i.p.), respectively. The duration of the anticonvulsant effects of YM90K and NBQX was 30 min, indicating that both compounds possess short action. In a global ischemia model, YM90K (15 mg/kg i.p. x 3), NBQX (30 mg/kg i.p. x 3) and CNQX (60 mg/kg i.p. x 3) significantly prevented the delayed neuronal death in the hippocampal CA1 region in Mongolian gerbils when administered 1 h after 5-min ischemia. In addition, the therapeutic time window for the neuroprotective effect of YM90K (30 mg/kg i.p. x 3) was 6 h. In a focal ischemia model, YM90K (30 mg/kg i.v. bolus+10 mg/kg/h for 4 h) reduced the volume of ischemic damage in the cerebral cortex in F344 rats. Thus, YM90K was shown to be a potent and selective antagonist for AMPA/kainate receptors in vitro and in vivo. This compound may provide a therapeutic effect in various neurodegenerative disorders such as ischemic stroke in which glutamate neurotoxicity is thought to play a critical role in neuronal damage.

摘要

我们研究了一种新型的α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)/海人藻酸受体拮抗剂[6-(1H-咪唑-1-基)-7-硝基-2,3-(1H,4H)-喹喔啉二酮盐酸盐(YM90K);原YM900]的药理学特性和神经保护作用,并与2,3-二羟基-6-硝基-7-氨磺酰基苯并(f)喹喔啉(NBQX)进行比较。YM90K能选择性地取代[3H]-AMPA结合(Ki = 0.084微摩尔),而在抑制[3H]-海人藻酸(Ki = 2.2微摩尔)、[3H]-L-谷氨酸(N-甲基-D-天冬氨酸敏感位点;Ki > 100微摩尔)和[3H]-甘氨酸(士的宁不敏感位点;Ki = 37微摩尔)与大鼠脑膜结合方面效力较弱。将YM90K与AMPA或海人藻酸共同注射到大鼠纹状体中,可保护胆碱能神经元免受AMPA或海人藻酸诱导的神经毒性。YM90K对DBA/2小鼠的听源性惊厥显示出强效抑制活性;YM90K和NBQX对强直性惊厥的半数有效剂量(ED50)分别为2.54和7.17毫克/千克(腹腔注射)。YM90K和NBQX的抗惊厥作用持续时间为30分钟,表明这两种化合物作用时间较短。在全脑缺血模型中,当在5分钟缺血后1小时给药时,YM90K(15毫克/千克腹腔注射×3次)、NBQX(30毫克/千克腹腔注射×3次)和CNQX(60毫克/千克腹腔注射×3次)可显著预防蒙古沙土鼠海马CA1区的迟发性神经元死亡。此外,YM90K(30毫克/千克腹腔注射×3次)的神经保护作用的治疗时间窗为6小时。在局灶性缺血模型中,YM90K(30毫克/千克静脉推注+10毫克/千克/小时,持续4小时)可减少F344大鼠大脑皮质缺血损伤的体积。因此,YM90K在体外和体内均被证明是一种强效且选择性的AMPA/海人藻酸受体拮抗剂。这种化合物可能在各种神经退行性疾病如缺血性卒中中发挥治疗作用,在缺血性卒中中,谷氨酸神经毒性被认为在神经元损伤中起关键作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验